The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.
Introduction
The nuclear farnesoid X receptor (FXR) is a key metabolic regulator governing the homeostasis of bile acids, lipids and glucose. [1, 2] It has a profound protective role in liver and has been identified as a valuable target for the treatment of metabolism-associated liver diseases, particularly non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). [3] [4] [5] This hepatic manifestation of the metabolic syndrome is considered as global health burden with alarming prevalence but there is no pharmacological treatment option to date. [6, 7] The FXR agonist obeticholic acid (1) [8] (Scheme 1) has shown great promise in NASH treatment in several clinical trials [5, 9] and has validated FXR as a valuable drug target.
Soluble epoxide hydrolase (sEH) as a downstream enzyme in the CYP-pathway of the arachidonic acid cascade converts epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs). [10] Since EETs are anti-inflammatory lipid mediators, sEH inhibition constitutes an anti-inflammatory strategy that was repeatedly shown to have considerable potential in NASH treatment. [11, 12] FXR activation in NASH is mainly effective through metabolic effects and antisteatotic activity, [5] sEH inhibition has anti-inflammatory and anti-fibrotic effects in liver. [13] Thus, combination of FXR activation and sEH inhibition may produce additive therapeutic efficacy in NASH. Additionally, a recent report [14] links FXR activation with induction of cytochrome P450 epoxygenases. This in turn increases sEH substrate concentrations which further illustrates potential synergies of FXR and sEH.
We have recently reported the development and characterization of the first-in-class dual FXR agonist/sEH inhibitor (FXRA/ sEHi) 2. [15] With its designed polypharmacological profile, this innovative multi-target agent [16] showed robust therapeutic efficacy in animal models of toxin-and diet-induced NASH by simultaneously exhibiting anti-steatotic, anti-fibrotic and antiinflammatory activity. [17] The dual mode of action was superior to pure FXR activation in these in vivo studies confirming the value of the multi-target approach.
In designing a triple modulator of soluble epoxide hydrolase (sEH), peroxisome proliferator-activated receptor γ (PPARγ) and cysteinyl leukotriene receptor 1 (CysLT 1 R) from zafirlukast (3) , [18] we also observed weak agonistic potency of 3 in a FXR-Gal4 hybrid assay (4.8-fold activation at 10 μM). [18] Full dose-response characterization of 3 in a more physiological full length FXR-ester 30, while 26 was coupled with 4-tert-butylbenzoic acid (31) using EDC*HCl and 4-DMAP to form ester 32. Alkaline hydrolysis of 27, 30 and 32 then yielded 4, 5 and 9 (Scheme 2). [18, 20] 6 and 7 were prepared accordingly using isonicotinic acid (33) or GW4064-derived building block 34 as N-substituents. The required isoxazolecarboxylate 34 was prepared according to the published procedure [21] from 2,6dichlorobenzaldehyde (35) which was transformed to aldoxime 36 using hydroxylamine hydrochloride followed by chlorination to 37 with NCS.
37 was cyclized with methyl isobutyrylacetate (38) to isoxazole 39 and alkaline hydrolysis of 39 yielded 34. Coupling of 25 with 33 or 34 using EDC*HCl and 4-DMAP to esters 40 and 41 followed by alkaline hydrolysis yielded 6 and 7 (Scheme 2). For the synthesis of 11, 5-nitroindole (17) was Nalkylated with diisopropylsulfate (42) to generate 43 which was then transformed to 11 in four further steps according to the synthesis of 5. 8 and 10 were prepared from N-methyl-5-nitroindole (18) which was coupled with methyl 4-formylbenzoate (47) or methyl 3-formylbenzoate (48) in presence of triethylsilane and trifluoroacetic acid [22] to 49 and 50. 49 and 50 were then reduced with H 2 and Pd(C) to anilines 51 and 52, and subsequently reacted with 4-tert-butylbenzoyl chloride (29) to generate 53 or 54 whose alkaline hydrolysis yielded 8 and 10 (Scheme 3).
Analogues 13, 15 and 16 with inverted indole orientation were prepared in a five-step procedure according to Scheme 4. 6-Nitroindole (55) was N-alkylated with 19, 56 or 57 to generate 58, 59 and 60. After reduction with H 2 and Pd(C) to anilines 61-63, coupling with 4-tert-butylbenzoic acid (31) in presence of EDC*HCl and 4-DMAP formed 64-66 and alkaline hydrolysis yielded 13, 15 and 16 (Scheme 4).
Benzimidazole analogue 14 was prepared from 6-nitro-1Hbenzimidazole (67) by N-alkylation with 19 to 68 followed by reduction with H 2 and Pd(C) to aniline 69, reaction with 4-tertbutylbenzoyl chloride (29) to 70 and alkaline hydrolysis to 14 (Scheme 5).
Preparation of 12 proceeded in a similar fashion as analogues 13, 15 and 16 starting with N-alkylation of 5nitroindole (17) with 19 to 71, followed by reduction of 71 with H 2 and Pd(C) to aniline 72. 72 was then reacted with 4-tertbutylbenzoyl chloride (29) to 73 and saponification of 73 yielded 12 (Scheme 6).
Biological Evaluation

4-16
were characterized in a full-length FXR reporter gene assay that relies on a firefly luciferase reporter under the control of the FXR response element from the promoter region of the bile salt export protein (BSEP) gene. [25, 26] In this assay, HeLa cells are transiently transfected with the reporter construct, constitutive expression plasmids coding for human full-length FXR and its heterodimer partner retinoid X receptor α (RXRα) as well as a constitutively expressed renilla luciferase as internal control for transfection efficiency and test compound toxicity. Inhibitory potency of 4-16 was determined in a sEH activity assay [27, 28] using recombinant human enzyme and (3-phenyloxiranyl)acetic acid cyano-(6-methoxynaphthalen-2-yl)methyl ester (PHOME) as fluorogenic substrate. CysLT 1 R antagonism was determined in a cell-based Ca 2 + -flux assay [29] in competition with 0.1 nM leukotriene D4.
Structure-Activity Relationship Analysis
As first step in optimizing 3 towards dual FXR/sEH modulators (Table 1) , we evaluated the effect of replacing the N-acyl sulfonamide moiety by a carboxylic acid (4) . According to SAR studies on 3 as CysLT 1 R antagonist, this structural change is accompanied by a remarkable, 500-fold loss in CysLT 1 R antagonistic potency (K i 0.3 nM vs. 157 nM) [20] and, for the development of dual FXR/sEH modulators according to the SOSA [19, 30] concept, reduction in activity on CysLT 1 R was desired. On sEH, 4 gained in inhibitory potency while the structural modification was not favored by FXR.
Molecular docking of 4 ( Figure 1 ) suggested a favorable binding mode to the sEH active site (PDB-ID: 3OTQ [23] ) with the urethane engaging polar contact with the catalytic Asp335 residue which is typical for sEH inhibitors. Additionally, the urethane carbonyl oxygen was bound to Tyr383 and Tyr466 and the carboxylate formed a hydrogen bond to Ser312. The cyclopentyl substituent though bound in a lipophilic environ- Figure 1 . Molecular docking of 4 in the sEH active site (PDB-ID: 3OTQ [23] ) and the ligand binding site of FXR (PDB-ID: 4QE8 [24] ) particularly suggested potential for structural optimization in the terminal cyclopentylurethane moiety. Docking was performed in MOE and visualized using UCSF Chimera. ment seemed to offer optimization potential by enabling a stacking interaction with Trp366 with an aromatic replacement. In the FXR ligand binding site (PDB-ID: 4QE8 [24] ), the carboxylate moiety of 4 formed a water-mediated hydrogen bond to Arg331 as exclusive polar contact while the urethane structure appeared not favored in its lipophilic environment close to Ile357, Met450, Leu451, and Trp469 further suggesting that this terminal residue might hold potential to enhance activity on FXR. Thus, to compensate the loss in activity on FXR resulting from the modification of 3 to 4, we aimed to introduce known FXR ligand moieties replacing the cyclopentylurethane in 4.
A 4-tert-butylbenzamide (5) known from various FXR partial agonist series [15, 31, 32] indeed strongly improved FXR agonistic potency but caused a loss in sEH inhibitory activity which is likely due to a weakening of the polar interaction with Asp335 when the urethane is replaced by an amide. The isoxazole "hammerhead" structure (6) derived from GW4064 and analogues, [33, 34] in contrast, further diminished activity on FXR while it was tolerated by sEH. The inactivity of 6 on FXR may be due to the rigid amide linker between isoxazole and indole but this moiety could not be replaced since the amide is the key pharmacophore element for sEH inhibition. [15, 35, 36] To mimic the isoxazole which forms key contacts with the FXR ligand binding site (His447 and Trp469 of FXR) [2, 37] with a sterically less demanding scaffold, we replaced the "hammerhead" structure with an isonicotinic amide (7) which indeed regained activity on FXR but was inactive on sEH. Thus, the 4-tert-butylbenzamide in 5 turned out as the most favored moiety to replace the urethane and was conserved for further structural optimization.
We then focused on the SAR of the methoxybenzoate in 6 and first removed the methoxy group (8) which promoted inhibitory potency on sEH but was not tolerated by FXR. Shifting the carboxylate residue from 4-position (6) to the 3position (9) diminished activity on both targets. However, combining removal of the methoxy group and the 3-benzoate geometry resulted in the first dual modulator 10 with low micromolar activity on FXR and sEH.
Next, we studied the SAR of the central indole scaffold of 6. Enlargement of the N-methyl substituent to an isopropyl moiety (11) was not favored by either target. The same held true when the substitution geometry was modified by linking central indole and methoxybenzoate via the indole nitrogen (12) . However, inverting the central indole while retaining the overall geometry in 13 strongly improved inhibitory potency on sEH and was also favored by FXR. Compared to 3, 13 comprises a 15-fold improved EC 50 value on FXR and equal activity on sEH but is remarkably less active on CysLT 1 R (IC 50 : < 0.001 μM [29] (3) vs.~1 μM (13, as estimated from the compound's activity at 1 μM) Figure 2a ). When we replaced the indole scaffold of 13 by a benzimidazole (14) , activity on both targets was diminished by approx. 10-fold.
In an attempt to combine the favored structural variations on the indole and the benzoate moieties, we merged the modifications of 10 and 13 in 3-benzoic acid derivative 15 which retained activity on sEH but was inactive on FXR. However, conserving the original 4-benzoate geometry resulted in the well-balanced dual modulator 16, which was even less active on the lead compound's original receptor target CysLT 1 R (IC 50 : < 0.001 μM [29] (3) vs. > 1 μM (16, as estimated from the compound's activity at 1 μM) Figure 2a ).
Selectivity profiling of the most favorable Zafirlukast derived FXRA/sEHi 13 and 16 demonstrated high selectivity over nuclear receptors related to FXR apart from marked RARα activation by 16 ( Figure 2b ). Moreover, the optimized descendants 13 and 16 comprised strongly reduced toxicity compared to 3 (Figure 2c ). While 3 caused dose-dependent anti-proliferative activity at concentrations of 1 μM and above, 13 and 16 had no toxic effect up to 10 μM.
13 and 16 were then assessed for FXR activation and sEH inhibition in a more physiological cellular setting in hepatocytes to probe target engagement in cells. Both compounds blocked EET conversion to DHETs in HepG2 cells demonstrating cellular sEH inhibition ( Figure 4a ). Moreover, 13 and 16 induced expression of FXR regulated genes organic solute transporter α (OSTα) and small heterodimer-partner (SHP) while the expression of the indirectly FXR regulated cholesterol 7α hydroxylase (CYP7 A1) was reduced upon treatment with 13 or 16 (Figure 4b) . Therein, both dual modulators behaved as partial FXR agonists and only caused a favorably modest effect on gene expression compared to the endogenous FXR activator CDCA.
To computationally assess the interaction of the optimized dual modulators 13 and 16 with FXR and sEH, we predicted their binding modes to both proteins by molecular docking (Figure 3 ). The co-crystal 3OTQ [23] served as structural template for sEH, while binding to FXR was studied based on the X-ray data of the FXR ligand binding domain in complex with a partial agonist (4QE8 [24] ) owing to the partial agonistic profile of 13 and 16.
Within the sEH active site, 13 and 16 formed similar favorable binding modes. As typical for sEH inhibitors, the amide nitrogen engaged a hydrogen bond with the catalytic Asp335 and the amide oxygen made polar contacts with Tyr383 and Tyr466. In addition, the carboxylic acid residues of 13 and 16 formed a hydrogen bond with Ser415 and the terminal benzamide aromatic ring made a stacking interaction with Trp336. No specific interactions were observed for the methoxy substituent of 13 which agrees with the almost identical sEH inhibitory potency of 13 and 16.
In the FXR ligand binding site, the predicted binding modes of 13 and 16 revealed water mediated hydrogen bonding of the carboxylate residues with Arg331 as exclusive polar contact. As observed for other partial agonists, [24] the tert-butylbenzamide moieties of 13 and 16 occupied the terminal region of the binding site where Trp454 is located leading to an outward conformation of this residue which results in partial FXR activation. The methoxy substituent of 13 favorably occupied a polar region of the binding site between His294 and Ser332 which agrees with the approx. 10-fold higher potency of 13 on FXR compared to 16.
Conclusions
The metabolic syndrome with its multiple manifestations including insulin resistance, dyslipidemia and NAFLD is a major global health burden with continuously increasing prevalence. [38] Despite a variety of approved drugs for several metabolic diseases, the therapy of this disease complex is not satisfying. For its multifactorial nature, multimodal treatment may be required to achieve improved clinical efficacy. In NASH, FXR activation demonstrated favorable anti-steatotic effects and countered fibrosis [5, 9] while sEH inhibition produced strong antiinflammatory activity in liver accompanied by anti-steatotic and anti-fibrotic action. [11, 12] The combination of these two unrelated mechanisms has the potential to generate synergistic efficacy for NASH treatment. [15, 17] Based on these considerations we have employed the CysLT 1 R antagonist Zafirlukast comprising side activities on FXR and sEH as lead compound and systematically optimized the scaffold to dual FXR activators/sEH inhibitors with markedly reduced activity on CysLT 1 R. The resulting Zafirlukast-derived FXRA/sEHi 13 and 16 inhibited sEH and [23] upper images) and the ligand binding site of FXR in partially active conformation (PDB-ID: 4QE8, [24] lower images). 13 and 16 form similar predicted binding modes in the sEH active site with the amide nitrogen participating in the typical hydrogen bond to the catalytic Asp335 residue and the amide oxygen interacting with Tyr383 and Tyr466. In addition, the benzamide aromatic ring makes a stacking interaction with Trp336 and the carboxylate moiety engages a hydrogen bond with Ser415. In the FXR ligand binding site, 13 and 16 interact with Arg331 in water mediated hydrogen bonds as exclusive polar contact. The tert-butylbenzamide moieties occupy the region of Trp454 which consequently obtains an outward conformation resulting in partial FXR activation. [24] The methoxy group of 13 occupies a polar region between His294 and Ser332 which agrees with the higher potency of 13 on FXR. Docking was performed in MOE and visualized using UCSF Chimera. activated FXR in hepatocytes (HepG2) demonstrating target engagement in a native cellular setting. Thus, the designed multi-target compounds are suitable for further evaluation as innovative agents to counter NASH and related metabolic diseases and may open new avenues to polypharmacological agents as superior future treatment options for the metabolic syndrome.
Experimental Section
Chemistry General: All chemicals and solvents were of reagent grade and used without further purification unless otherwise specified. All reactions were conducted in oven-dried glassware under argon atmosphere and in absolute solvents. NMR spectra were recorded on a Bruker AV 500, Bruker AV 300 or a Bruker am250xp spectrometer (Bruker Corporation, Billerica, MA, USA). Chemical shifts (δ) are reported in ppm relative to tetramethylsilane (TMS) as reference. Multiplicity is reported: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; m, multiplet. Approximate coupling constants (J) are given in hertz (Hz). Mass spectra were obtained on a VG Platform II (Thermo Fischer Scientific, Inc., Waltham, MA, USA) using electrospray ionization (ESI). High-resolution mass spectra were recorded on a MALDI LTQ ORBITRAP XL instrument (Thermo Fisher Scientific). Compounds were purified by preparative HPLC using a Shimadzu preparative LC-20 A Prominence (Shimadzu, Kyoto, Japan) with the following conditions: column, Luna Compound 4 as well as its precursors 18, 19, 23 and 27 have been reported previously. [18] (5) : Methyl 4-((5-(4-(tert-butyl)benzamido)-1methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (30, 0.22 g, 0.45 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (15 mL), H 2 O (10 mL) and lithium hydroxide (33 mg, 1.4 mmol, 3.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 5 as colorless solid (0.13 g, 62 %). 1 (6) : Methyl 4-((5-(3-(2,6-dichlorophenyl)-5-isopropylisoxazole-4carboxamido)-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (40, 10 mg, 0.017 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (10 mL), H 2 O (5 mL) and lithium hydroxide (24 mg, 0.10 mmol, 5.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 6 as a yellow solid (1.2 mg, 10 %). 1 13 (7): Methyl 4-((5-(isonicotinamido)-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (41, 0.14 g, 0.33 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (10 mL), H 2 O (5 mL) and lithium hydroxide (24 mg, 0.99 mmol, 3.0 eq) were added, and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 7 as a yellow solid (53 mg, 38 %). 1 13 (8): Methyl 4-((5-(4-(tert-butyl)benzamido)-1-methyl-1H-indol-3-yl)methyl)benzoate (53, 0.35 g, 0.77 mmol, 1.0 eq) was dissolved in EtOH (20 mL), H 2 O (10 mL) and lithium hydroxide (55 mg, 2.3 mmol, 3.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 8 as pale purple solid (0.19 g, 58 %). 1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 3-((5-(4-tert-Butylbenzamido)-1-methyl-1H-indol-3-yl)methyl)-4methoxybenzoic acid (9) : Methyl 3-((5-(4-tert-butylbenzamido)-1methyl-1H-indol-3-yl)methyl)-4-methoxybenzoate (32, 12 mg, 0.02 mmol, 1.0 eq) was dissolved in EtOH (20 mL), H 2 O (10 mL) and lithium hydroxide (2.4 mg, 0.1 mmol, 5.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 9 as yellow solid (5 mg, 53 %). 1 13 (10): Methyl 3-((5-(4-(tert-butyl)benzamido)-1-methyl-1H-indol-3-yl)methyl)benzoate (54, 0.32 g, 0.70 mmol, 1.0 eq) was dissolved in EtOH (20 mL), H 2 O (10 mL) and lithium hydroxide (50 mg, 2.1 mmol, 3.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 10 as pale purple solid (0.26 g, 87 %). 1 
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3-((5-(4-(tert-Butyl)benzamido)-1-methyl-1H-indol-3-yl)methyl) benzoic acid
4-((5-(4-(tert-Butyl)benzamido)-1-isopropyl-1H-indol-3-yl)methyl)-3-methoxybenzoic
acid (11) : Methyl 4-((5-(4-(tert-butyl) benzamido)-1-isopropyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (46, 82 mg, 0.16 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (10 mL), H 2 O (5 mL) and lithium hydroxide (12 mg, 0.48 mmol, 3.0 eq) were added, and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 11 as a colorless solid (0.03 g, 38 %). 1 (12) : Methyl 4-((5-(4-(tert-butyl)benzamido)-1H-indol-1-yl)methyl)-3-methoxybenzoate (73, 89 mg, 0.19 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (15 mL), H 2 O (10 mL) and lithium hydroxide (23 mg, 0.95 mmol, 5.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 12 as white solid (0.08 g, 93 %). 1 (13): Methyl 4-((6-(4-(tert-butyl)benzamido)-1H-indol-1-yl)methyl)-3-methoxybenzoate (66, 42 mg, 0.09 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (15 mL), H 2 O (10 mL) and lithium hydroxide (11 mg, 0.45 mmol, 5.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 13 as yellow solid (40 mg, 98 %). 13 (14) : Methyl 4-((6-(4-(tert-butyl)benzamido)-1H-benzoimidazol-1-yl)methyl)-3-methoxybenzoate (70, 0.41 g, 0.87 mmol, 1.0 eq) was dissolved in THF (10 mL) and EtOH (15 mL), H 2 O (10 mL) and lithium hydroxide (0.10 g, 4.4 mmol, 5.0 eq) were added, and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 14 as colorless solid (0.22 g, 54 %). 1 (15) : Methyl 3-((6-(4-(tert-butyl)benzamido)-1H-indol-1-yl)methyl) benzoate (65, 0.41 g, 0.93 mmol, 1.0 eq) was dissolved in EtOH (30 mL), H 2 O (10 mL) and lithium hydroxide (0.11 g, 4.7 mmol, 5.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatog-raphy using EtOAc/hexane (1 : 1) as mobile phase. 15 was obtained as a colorless solid (0.28 g, 70 %). 1 6-(4-(tert-Butyl) benzamido)-1H-indol-1-yl)methyl)benzoic acid (16) : Methyl 4-((6-(4-(tert-butyl)benzamido)-1H-indol-1-yl)methyl) benzoate (64, 0.53 g, 1.2 mmol, 1.0 eq) was dissolved in EtOH (30 mL), H 2 O (10 mL) and lithium hydroxide (0.14 g, 6.0 mmol, 5.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 1) as mobile phase. 16 was obtained as a yellow solid (0.41 g, 80 %). 1 (18): 5-Nitro-1H-indole (17, 0.48 g, 3.0 mmol, 1.0 eq) was dissolved in DMF (abs., 20 mL), NaOH (0.25 g, 6.3 mmol, 2.1 eq) was added and the mixture was stirred for 10 min at 40°C. Dimethyl sulfate (0.34 mL, 3.6 mmol, 1.2 eq) was carefully added and the mixture was stirred for another 2 h at 40°C. Then, H 2 O was added to precipitate the title compound as a yellow solid (0.47 g, 91 %). 1 Methyl 4-(bromomethyl)-3-methoxybenzoate (19) : Methyl 3-methoxy-4-methylbenzoate (21, 4.26 g, 23.7 mmol, 1.00 eq) was dissolved in CHCl 3 (abs., 150 mL). N-Bromosuccinimide (5.10 g, 28.4 mmol, 1.20 eq) and azobisisobutyronitrile (0.38 g, 2.3 mmol, 0.10 eq) were added and the mixture was refluxed for 12 h. After cooling to room temperature, the precipitated title compound was filtered off as a colorless solid (4.48 g, 73 %). 1 (20) : Methyl 4-methoxy-3-methylbenzoate (22, 0.48 g, 2.7 mmol, 1.0 eq) was dissolved in CHCl 3 (abs., 30 mL). N-Bromosuccinimide (0.57 g, 3.2 mmol, 1.2 eq) and azobisisobutyronitrile (44 mg, 0.27 mmol, 0.10 eq) were added and the mixture was refluxed for 12 h. After cooling to room temperature, the precipitated title compound was filtered off as a colorless solid (0.61 g, 88 %). 1 Methyl 3-methoxy-4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoate (23): 1-Methyl-5-nitro-1H-indole (18, 699 mg, 4.00 mmol, 1.00 eq) and methyl 4-(bromomethyl)-3-methoxybenzoate (19, 1.00 g, 4.00 mmol, 1.00 eq) were dissolved in 1,4-dioxane (abs., 50 mL), FeCl 3 (1.94 g, 12.0 mmol, 3.00 eq) was carefully added, and the mixture was stirred at room temperature for 12 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 5) as mobile phase to obtain 23 as yellow solid (0.53 g, 38 %). 13 13 (20 mL) and Pd(C) (loading 10 % w/w, 43 mg, 0.040 mmol, 0.10 eq) was added. The suspension was stirred at room temperature under H 2 atmosphere for 6 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum to obtain the title compound as pale purple solid (95 mg, 73 %). 1 (30) : Methyl 4-((5-amino-1-methyl-1Hindol-3-yl)methyl)-3-methoxybenzoate (25, 0.24 g, 0.74 mmol, 1.0 eq) and 4-tert-butylbenzoyl chloride (29, 0.19 g, 0.96 mmol, 1.3 eq) were dissolved in THF (abs., 10 mL), DMF (abs., 2 mL) and pyridine (0.18 mL, 2.2 mmol, 3.0 eq). The mixture was stirred at room temperature for 12 h. After acidification with aqueous hydrochloric acid (2 N, 15 mL), the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 3) as mobile phase. 30 was obtained as a yellow solid (0.22 g, 61 %). 1 13 (32): 4-tert-Butylbenzoic acid (31, 62 mg, 0.35 mmol, 1.2 eq) was dissolved in CHCl 3 (abs., 10 mL). EDC·HCl (67 mg, 0.35 mmol, 1.2 eq), 4-DMAP (54 mg, 0.44 mmol, 1.5 eq) and methyl 3-((5-amino-1-methyl-1H-indol-3-yl)methyl)-4methoxybenzoate (26, 95 mg, 0.29 mmol, 1.0 eq) were added. The reaction mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (10 %, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 3) as mobile phase to obtain 32 as a yellow solid (12 mg, 8 %). 1 13 (34) : Methyl 3-(2,6-dichlorophenyl)-5-isopropylisoxazole-4-carboxylate (39, 0.75 g, 2.4 mmol, 1.0 eq) was dissolved in EtOH (30 mL), H 2 O (10 mL) and lithium hydroxide (0.31 g, 7.2 mmol, 3.0 eq) were added and the mixture was stirred at room temperature for 16 h. Aqueous hydrochloric acid (2 N, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (5 : 1) as mobile phase to obtain the title compound as colorless solid (0.35 g, 49 %). 1 13 (37) : N-chlorosuccinimide (0.502 g, 3.76 mmol, 1.00 eq) was slowly added at room temperature to a solution of 2,6-dichlorobenzaldehyde oxime (36, 0.714 g, 3.76 mmol, 1.00 eq) in DMF (abs., 8 mL). The reaction mixture was stirred for 5 h at room temperature. H 2 O (20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. 37 was obtained as a colorless solid (0.836, 99 %) and was used without further purification. 1 (39) : A stirred solution of methyl isobutyrylacetate (38, 0.544 g, 3.77 mmol, 1.00 eq) in THF (abs., 50 mL) was treated with a solution of sodium methoxide (0.76 mL, 0.50 M in MeOH) followed by a solution of 2,6-dichloro-N-hydroxybenzimidoyl chloride (37, 0.848 g, 3.77 mmol, 1.00 eq) in THF (abs., 20 mL). After stirring at room temperature for 16 h, H 2 O (20 mL) was added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 5) as mobile phase to obtain the title compound as colorless solid (0.75 g, 63 %). 1 (40) : 3-(2,6-Dichlorophenyl)-5-isopropylisoxazole-4-carboxylic acid (34, 0.18 g, 0.50 mmol, 1.0 eq) was dissolved in CHCl 3 (abs., 20 mL). EDC·HCl (0.12 g, 0.60 mmol, 1.2 eq), 4-DMAP (92 mg, 0.75 mmol, 1.5 eq) and methyl 4-((5-amino-1-methyl-1H-indol-3-yl) methyl)-3-methoxybenzoate (25, 0.19 g, 0.60 mmol, 1.2 eq) were added. The mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by preparative HPLC to obtain 40 as a yellow solid (50 mg, 14 %). 1 (41) : Isonicotinic acid (33, 0.12 g, 1.1 mmol, 1.0 eq) was dissolved in CHCl 3 (abs., 20 mL). EDC·HCl (0.46 g, 2.4 mmol, 2.4 eq), 4-DMAP (0.46 g, 3.0 mmol, 3.0 eq) and methyl 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (25, 0.32 g, 1.0 mmol, 1.0 eq) were added. The reaction mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (2 N, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 5) as mobile phase to obtain 41 as a yellow solid (0.14 g, 33 %). 1 13 C NMR (126 MHz, DMSO) δ = 167. 33, 167.30, 156.66, 150.20, 142.31, 134.65, 134.13, 130.35, 129.79, 129.32, 128.16, 127.09, 126.98, 121.61, 115.98, 113.14, 111.48, 110.89, 110.70, 109.56, 55.48, 35.55, 32.40 . MS (ESI +): no molecular ion. (43): 5-Nitro-1H-indole (17, 2.0 g, 12 mmol, 1.0 eq) was dissolved in DMF (abs., 20 mL), NaOH (1.0 g, 25 mmol, 2.1 eq) was added and the mixture was stirred for 10 min at 40°C. Diisopropyl sulfate (2.5 g, 14 mmol, 1.2 eq) was carefully added and the mixture was stirred for another 2 h at 40°C. Then, H 2 O was added to precipitate the title compound as a yellow solid (0.5 g, 20 %). 1 (44): 1-Isopropyl-5-nitro-1H-indole (43, 0.50 g, 2.5 mmol, 1.0 eq) and methyl 4-(bromomethyl)-3-methoxybenzoate (19, 0.65 g, 2.5 mmol, 1.0 eq) were dissolved in 1,4-dioxane (abs., 30 mL), FeCl 3 (1.2 g, 7.5 mmol, 3.0 eq) was carefully added, and the mixture was stirred at room temperature for 12 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 5) as mobile phase to obtain the title compound as yellow solid (0.15 g, 16 %). 1 13 (45) : Methyl 4-((1-isopropyl-5-nitro-1H-indol-3-yl)methyl)-3-methoxybenzoate (44, 0.15 g, 0.39 mmol, 1.0 eq) was dissolved in MeOH (15 mL) and Pd(C) (loading 10 % w/w, 43 mg, 0.04 mmol, 0.1 eq) was added. The suspension was stirred at room temperature under H 2 atmosphere for 6 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum to obtain the title compound as pale purple solid (0.12 g, 86 %). 1 13 (46) : Methyl 4-((5-amino-1-isopropyl-1H-indol-3-yl)methyl)-3-methoxybenzoate (45, 0.10 g, 0.28 mmol, 1.0 eq) and 4-tert-butylbenzoyl chloride (29, 71 mg, 0.36 mmol, 1.3 eq) were dissolved in THF (abs., 20 mL), DMF (abs., 2 mL) and pyridine (0.07 mL, 0.84 mmol, 3.0 eq). The mixture was stirred at room temperature for 12 h. After acidification with aqueous hydrochloric acid (2 N, 15 mL), the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using 4-((1-methyl-5-nitro-1H-indol-3-yl) methyl)benzoate (49): A solution of 1-methyl-5-nitro-1H-indole (18, 0.36 g, 2.0 mmol, 1.0 eq) and methyl 4-formylbenzoate (47, 0.33 g, 2.0 mmol, 1.0 eq) in CH 2 Cl 2 (abs., 30 mL) was cooled to 0°C, and triethylsilane (0.96 mL, 6.0 mmol, 3.0 eq) and trifluoroacetic acid (0.31 mL, 4.0 mmol, 2.0 eq) were added. After 10 min at 0°C, the ice bath was removed and the mixture was stirred for 5 h. Aqueous NaHCO 3 (saturated, 30 mL) was added, phases were separated, and the aqueous layer was extracted with CH 2 Cl 2 (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (10 : 1) as mobile phase to yield 49 as a yellow solid (0.29 g, 45 %). 1 
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Methyl 3-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoate (50):
A solution of 1-methyl-5-nitro-1H-indole (18, 0.36 g, 2.0 mmol, 1.0 eq) and methyl 3-formylbenzoate (48, 0.33 g, 2.0 mmol, 1.0 eq) in CH 2 Cl 2 (abs., 30 mL) was cooled to 0°C, and triethylsilane (0.96 mL, 6.0 mmol, 3.0 eq) and trifluoroacetic acid (0.31 mL, 4.0 mmol, 2.0 eq) were added. After 10 min at 0°C, the ice bath was removed and the mixture was stirred for 5 h. Aqueous NaHCO 3 (saturated, 30 mL) was added, phases were separated, and the aqueous layer was extracted with CH 2 Cl 2 (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (10 : 1) as mobile phase to yield 50 as a yellow solid (0.31 g, 48 %). 1 13 
Methyl 4-((5-amino-1-methyl-1H-indol-3-yl)methyl)benzoate (51):
Methyl 4-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoate (49, 0.29 g, 0.89 mmol, 1.0 eq) was dissolved in MeOH (20 mL) and Pd(C) (loading 10 % w/w, 96 mg, 0.089 mmol, 0.10 eq) was added. The suspension was stirred at room temperature under H 2 atmosphere for 6 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum to obtain the title compound as pale purple solid (0.22 g, 85 %). 13 
Methyl 3-((5-amino-1-methyl-1H-indol-3-yl)methyl)benzoate (52):
Methyl 3-((1-methyl-5-nitro-1H-indol-3-yl)methyl)benzoate (50, 0.31 g, 0.95 mmol, 1.0 eq) was dissolved in MeOH (20 mL) and Pd(C) (loading 10 % w/w, 0.11 g, 0.10 mmol, 0.10 eq) was added. The suspension was stirred at room temperature under H 2 atmosphere for 6 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum to 1 H NMR (500 MHz, DMSO) δ = 7.83 (d, J = 7.7, 2H), 7.75 (d, J = 7.9, 2H), 7.57 (d, J = 7.6, 2H), 7.47 (t, J = 7.6, 2H), 7.44-7.39 (m, 2H), 4.56 (s, 2H), 3.85 (s, 3H), 3.84 (s, 3H). 13 5-(4-(tert-butyl) benzamido)-1-methyl-1H-indol-3-yl) methyl)benzoate (53): Methyl 4-((5-amino-1-methyl-1H-indol-3-yl) methyl)benzoate (51, 0.30 g, 1.0 mmol, 1.0 eq) and 4-tert-butylbenzoyl chloride (29, 0.25 g, 1.3 mmol, 1.3 eq) were dissolved in THF (abs., 30 mL), DMF (abs., 5 mL) and pyridine (0.40 mL, 5.0 mmol, 5.0 eq). The mixture was stirred at room temperature for 12 h. After acidification with aqueous hydrochloric acid (2 N, 30 mL), the mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 1) as mobile phase. 53 was obtained as a pale purple solid (0.35 g, 65 %). 13 (54): Methyl 3-((5-amino-1-methyl-1H-indol-3-yl) methyl)benzoate (52, 0.30 g, 1.0 mmol, 1.0 eq) and 4-tert-butylbenzoyl chloride (29, 0.25 g, 1.3 mmol, 1.3 eq) were dissolved in THF (abs., 30 mL), DMF (abs., 5 mL) and pyridine (0.40 mL, 5.0 mmol, 5.0 eq). The mixture was stirred at room temperature for 12 h. After acidification with aqueous hydrochloric acid (2 N, 30 mL), the mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 1) as mobile phase to obtain 54 as a pale purple solid (0.32 g, 59 %). 1 13 Methyl 4-((6-nitro-1H-indol-1-yl)methyl)benzoate (58): 6-Nitro-1Hindole (55, 0.30 g, 1.9 mmol, 1.0 eq), potassium carbonate (0.52 g, 3.8 mmol, 2.0 eq) and methyl 4-(bromomethyl)benzoate (56, 0.43 g, 1.9 mmol, 1.0 eq) were dissolved in DMF (abs., 20 mL). The mixture was stirred under reflux for 12 h. After cooling to room temperature, aqueous hydrochloric acid (5 %, 30 mL) was added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (30 : 1) as mobile phase. 58 was obtained as a yellow solid (0.57 g, 97 %). 1 13 3-((6-nitro-1H-indol-1-yl) methyl)benzoate (59): 6-Nitro-1Hindole (55, 0.30 g, 1.9 mmol, 1.0 eq), potassium carbonate (0.52 g, 3.8 mmol, 2.0 eq) and methyl 3-(bromomethyl)benzoate (57, 0.43 g, 1.9 mmol, 1.0 eq) were dissolved in DMF (abs., 20 mL). The mixture was stirred under reflux for 12 h. After cooling to room temperature, aqueous hydrochloric acid (5 %, 30 mL) was added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (10 : 1) as mobile phase. 59 was obtained as a yellow solid (0.48 g, 81 %). 1 ). 13 After cooling to room temperature, aqueous hydrochloric acid (5 %, 30 mL) was added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (30 : 1) as mobile phase to obtain 60 as a yellow solid (0.13 g, 38 %). 1 13 13 The suspension was stirred at room temperature under H 2 atmosphere for 6 h. The mixture was then filtered through celite, the filtrate was dried over MgSO 4 , and the solvent was evaporated in vacuum to obtain the title compound as pale purple solid (0.07 g, 59 %). 1 6-(4-(tert-butyl) benzamido)-1H-indol-1-yl)methyl)benzoate (64): 4-tert-Butylbenzoic acid (31, 0.24 g, 1.4 mmol, 1.2 eq) was dissolved in CHCl 3 (abs., 20 mL). EDC·HCl (0.26 g, 1.4 mmol, 1.2 eq), 4-DMAP (0.20 g, 1.7 mmol, 1.5 eq) and methyl 4-((6-amino-1H-indol-1-yl)methyl)benzoate (61, 0.32 g, 1.1 mmol, 1.0 eq) were added. The reaction mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (10 %, 10 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using toluene/acetone (10 : 1) as mobile phase to obtain 64 as pale purple solid (0.47 g, 97 %). 1 6-(4-(tert-butyl) benzamido)-1H-indol-1-yl)methyl)benzoate (65): 4-tert-Butylbenzoic acid (31, 0.34 g, 1.9 mmol, 1.2 eq) was dissolved in CHCl 3 (abs., 20 mL). EDC·HCl (0.36 g, 1.9 mmol, 1.2 eq), 4-DMAP (0.29 g, 2.4 mmol, 1.5 eq) and methyl 3-((6-amino-1H-indol-1-yl)methyl)benzoate (62, 0.45 g, 1.6 mmol, 1.0 eq) were added. The reaction mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (10 %, 20 mL) was then added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using toluene/acetone (10 : 1) as mobile phase. 65 was obtained as a yellow solid (0.41 g, 59 %). 1 6-(4-(tert-butyl) benzamido)-1H-indol-1-yl)methyl)-3methoxybenzoate (66): 4-tert-Butylbenzoic acid (31, 50 mg, 0.28 mmol, 1.2 eq) was dissolved in CHCl 3 (abs., 10 mL). EDC·HCl (54 mg, 0.28 mmol, 1.2 eq), 4-DMAP (43 mg, 0.35 mmol, 1.5 eq) and methyl 4-((6-amino-1H-indol-1-yl)methyl)-3-methoxybenzoate (63, 70 mg, 0.23 mmol, 1.0 eq) were added. The reaction mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (10 %, 10 mL) was then added, phases were separated, and the product was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over MgSO 4 , the solvents were evaporated in vacuum. Methyl 3-methoxy-4-((6-nitro-1H-benzimidazol-1-yl)methyl)benzoate (68): 6-Nitro-1H-benzimidazole (67, 0.33 g, 2.0 mmol, 1.0 eq), potassium carbonate (0.52 g, 2.0 mmol, 2.0 eq) and methyl 4-(bromomethyl)-3-methoxybenzoate (19, 0.52 g, 2.0 mmol, 1.0 eq) were dissolved in DMF (abs., 20 mL). The mixture was stirred under reflux for 12 h. After cooling to room temperature, aqueous hydrochloric acid (5 %, 30 mL) was added, phases were separated, and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (10 : 1) as mobile phase. 68 was obtained as a yellow solid (0.45 g, 66 %). 1 13 (4-(tert-butyl) benzamido)-1H-benzoimidazol-1-yl) methyl)-3-methoxybenzoate (70): Methyl 4-((6-amino-1H-benzoimidazol-1-yl)methyl)-3-methoxybenzoate (69, 0.50 g, 1.6 mmol, 1.0 eq) and 4-tert-butylbenzoyl chloride (29, 0.41 g, 2.1 mmol, 1.3 eq) were dissolved in THF (abs., 50 mL), DMF (abs., 10 mL) and pyridine (0.39 mL, 4.8 mmol, 3.0 eq). The mixture was stirred at room temperature for 12 h. After acidification with aqueous hydrochloric acid (2 N, 30 mL), the mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 5) as mobile phase to obtain 70 as a yellow solid (0.41 g, 55 %). 1 were dried over MgSO 4 , and the solvents were evaporated in vacuum. The crude product was purified by column chromatography using toluene/acetone (10 : 1) as mobile phase. 71 was obtained as a yellow solid (0.16 g, 47 %). 1 (4-(tert-butyl) benzamido)-1H-indol-1-yl)methyl)-3methoxybenzoate (73): 4-tert-Butylbenzoic acid (31, 0.16 g, 0.89 mmol, 1.2 eq) was dissolved in CHCl 3 (abs., 20 mL). EDC·HCl (0.17 g, 0.89 mmol, 1.2 eq), 4-DMAP (0.29 g, 1.1 mmol, 1.5 eq) and methyl 4-((5-amino-1H-indol-1-yl)methyl)-3-methoxybenzoate (72, 0.23 g, 0.74 mmol, 1.0 eq) were added. The mixture was stirred at 50°C for 12 h. Aqueous hydrochloric acid (10 %, 20 mL) was then added, phases were separated, and the product was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO 4 , and the solvents were evaporated in vacuum. Further purification was performed by column chromatography using EtOAc/hexane (1 : 3) as mobile phase. 73 was obtained as a yellow solid (0.1 g, 29 %). 1 13 
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In vitro Pharmacology
FXR transactivation assay:
Plasmids: pcDNA3-hFXR [39] contains the sequence of human FXR. pSG5-hRXR [40] contains the sequence of human RXRα. pGL3basic (Promega Corporation, Fitchburg, WI, USA) was used as a reporter plasmid and contains a shortened construct of the promotor of the bile salt export protein (BSEP) cloned into the SacI/NheI cleavage site in front of the luciferase gene. [41] pRL-SV40 (Promega) served as a control for normalization of transfection efficiency and cell growth. Assay procedure: HeLa cells were grown in DMEM high glucose supplemented with 10 % fetal calf serum (FCS), sodium pyruvate (1 mM), penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37°C and 5 % CO 2 . 24 h before transfection, HeLa cells were seeded in 96-well plates with a density of 8000 cells per well. 3.5 h before transfection, medium was changed to DMEM high glucose, supplemented with sodium pyruvate (1 mM), penicillin (100 U/mL), streptomycin (100 μg/mL) and 0.5 % charcoal-stripped FCS. Transient transfection of HeLa cells with BSEP-pGL3, pRL-SV40 and the expression plasmids pcDNA3-hFXR and pSG5-hRXR was carried out using calcium phosphate transfection method. 16 h after transfection, medium was changed to DMEM high glucose, supplemented with sodium pyruvate (1 mM), penicillin (100 U/mL), streptomycin (100 μg/mL) and 0.5 % charcoal-stripped FCS. 24 h after transfection, medium was changed to DMEM without phenol red, supplemented with sodium pyruvate (1 mM), penicillin (100 U/mL), streptomycin (100 μg/mL), L-glutamine (2 mM) and 0.5 % charcoal-stripped FCS, now additionally containing 0.1 % DMSO and the respective test compound or 0.1 % DMSO alone as untreated control. Each concentration was tested in triplicate wells and each experiment was repeated independently at least three times. Following 24 h incubation with the test compounds, cells were assayed for luciferase activity using Dual-Glo™ Luciferase Assay System (Promega) according to the manufacturer's protocol. Luminescence was measured with a Tecan Infinite M200 luminometer (Tecan Deutschland GmbH, Crailsheim, Germany) or a Tecan Spark luminometer (Tecan). Normalization of transfection efficiency and cell growth was done by division of firefly luciferase data by renilla luciferase data multiplied by 1000 resulting in relative light units (RLU). Fold activation was obtained by dividing the mean RLU of the tested compound at a respective concentration by the mean RLU of untreated control. Relative activation was obtained by dividing the fold activation of the tested compound at a respective concentration by the fold activation of FXR full agonist GW4064 at 3 μM. EC 50 and standard deviation values were calculated with the mean relative activation values of at least three independent experiments set up in triplicates by SigmaPlot 12.5 (Systat Software GmbH, Erkrath, Germany) using a four-parameter logistic regression. The assay was validated with FXR agonists OCA (EC 50 = 0.16 � 0.02 μM, 87 � 3% rel. max. act.) and GW4064 (EC 50 = 0.51 � 0.16 μM, 3 μM defined as 100 %). [32, 42] Hybrid reporter gene assays for nuclear receptors: Plasmids: The Gal4-fusion receptor plasmids pFA-CMV-hPPARα-LBD, [43] pFA-CMV-hPPARγ-LBD, [43] pFA-CMV-hPPARδ-LBD, [43] pFA-CMV-hLXRα-LBD, [44] pFA-CMV-hLXRβ-LBD, [44] pFA-CMV-hRXRα-LBD, [26] pFA-CMV-hRARα-LBD [26] and pFA-CMV-hCAR-LBD [26] coding for the hinge region and ligand binding domain (LBD) of the canonical isoform of the respective nuclear receptor have been reported previously. pFR-Luc (Stratagene, Agilent Technologies, Santa Clara, California, USA) was used as reporter plasmid and pRL-SV40 (Promega) for normalization of transfection efficiency and cell growth. Assay procedure: HEK293T cells were grown in DMEM high glucose, supplemented with 10 % FCS, sodium pyruvate (1 mM), penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37°C and 5 % CO 2 . The day before transfection, HEK293T cells were seeded in 96-well plates (3 · 10 4 cells/well). Before transfection, medium was changed to Opti-MEM without supplements. Transient transfection was carried out using Lipofectamine LTX reagent (Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer's protocol with pFR-Luc (Stratagene), pRL-SV40 (Promega) and the corresponding Gal4-fusion nuclear receptor plasmid. 5 h after transfection, medium was changed to Opti-MEM supplemented with penicillin (100 U/mL), streptomycin (100 μg/mL), now additionally containing 0.1 % DMSO and the respective test compound or 0.1 % DMSO alone as untreated control. Each concentration was tested in duplicates and each experiment was repeated independently at least three times. Following overnight (14-16 h) incubation with the test compounds, cells were assayed for luciferase activity using Dual-Glo™ Luciferase Assay System (Promega) according to the manufacturer's protocol. Luminescence was measured with a Tecan Spark luminometer (Tecan). Normalization of transfection efficiency and cell growth was done by division of firefly luciferase data by renilla luciferase data and multiplying the value by 1000 resulting in relative light units (RLU). Fold activation was obtained by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 
